PubRank

R I Griffiths

Author PubWeight™ 19.22‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Costs and charges associated with three alternative techniques of hysterectomy. N Engl J Med 1996 3.35
2 Comparison of the rating scale and the standard gamble in measuring patient preferences for outcomes of gallstone disease. Med Decis Making 1995 1.54
3 Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients. Am J Kidney Dis 1993 1.48
4 Roles of muscle activity and load on the relationship between muscle spindle length and whole muscle length in the freely walking cat. Prog Brain Res 1989 1.29
5 Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. JAMA 1992 1.13
6 Early dosing practices and effectiveness of recombinant human erythropoietin. Kidney Int 1993 1.07
7 Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study. Vasc Med 1999 1.01
8 Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 1993 0.94
9 Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients. J Am Soc Nephrol 1994 0.93
10 An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer. Ann Oncol 2011 0.93
11 The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients. Med Care 1994 0.93
12 Health care utilization and mortality among elderly patients with myelodysplastic syndromes. Ann Oncol 2010 0.90
13 Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease. J Am Soc Nephrol 1993 0.86
14 Local cerebral blood flow and the electrocorticogram during sodium nitroprusside hypotension. Anaesth Intensive Care 1978 0.78
15 Catheter use is high even among hemodialysis patients with a fistula or graft. Kidney Int 2006 0.78
16 The clinical-economic trial: promise, problems, and challenges. Control Clin Trials 1995 0.77
17 Prostate cancer screening in the workplace. Employer costs. AAOHN J 1998 0.76
18 A workplace breast cancer screening program. Costs and components. AAOHN J 1998 0.75
19 One-year costs of second-line therapies for depression. J Clin Psychiatry 2000 0.75
20 Cost effectiveness of laparoscopic surgery: from whose perspective? J Laparoendosc Surg 1993 0.75